Pancreatic Cancer Prognosis and Treatment Guidelines

Introduction to Prognosis

The American College of Surgeons and oncology experts agree that pancreatic cancer has a poor prognosis, with an overall 5-year survival rate below 5%, though patients who undergo complete surgical resection followed by adjuvant chemotherapy can achieve 5-year survival approaching 25-30% 1
The European Society for Medical Oncology notes that 50-60% of patients have metastatic disease at presentation 1
The National Comprehensive Cancer Network guidelines state that the remaining 30-40% have locally advanced, unresectable disease 2

The American Joint Committee on Cancer recommends that R0 resection with negative margins is a favorable prognostic factor 2, 3, 4
The European Society for Medical Oncology states that lymph node ratio <0.2 is a favorable prognostic factor 2, 5
The National Comprehensive Cancer Network guidelines indicate that tumor size ≤2 cm (T1) is a favorable prognostic factor 5, 6
The American College of Surgeons notes that normal post-resection CA19.9 is a favorable prognostic factor 3, 6
The European Society for Medical Oncology recommends that treatment at high-volume centers with experienced surgical teams is a favorable prognostic factor 7, 4

The National Comprehensive Cancer Network guidelines recommend that patients with resectable disease should proceed directly to surgical resection (pancreaticoduodenectomy for head tumors, distal pancreatectomy for body/tail tumors) with R0 resection as the primary goal 2, 5, 6
The European Society for Medical Oncology states that patients should receive 6 months of adjuvant gemcitabine or 5-FU chemotherapy after surgery 2, 5
The American College of Surgeons notes that neoadjuvant chemotherapy or chemoradiotherapy may be considered for borderline resectable or locally advanced tumors to achieve tumor downsizing 2, 3
The National Comprehensive Cancer Network guidelines recommend that patients with metastatic disease should receive combination chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) for fit patients (ECOG 0-1) 2

The European Society for Medical Oncology warns that preoperative biliary stenting should be avoided unless surgery cannot be performed expeditiously, as it increases complications 2
The American College of Surgeons notes that percutaneous biopsy should not be performed in potentially resectable cases; use EUS-guided biopsy only when imaging is ambiguous 2
The National Comprehensive Cancer Network guidelines state that extended lymphadenectomy provides no survival benefit over standard lymphadenectomy 2, 5, 6
The European Society for Medical Oncology recommends that laparoscopy may detect occult peritoneal/liver metastases in <15% of cases, particularly useful for left-sided large tumors or elevated CA19.9 2, 7